AgomAb Therapeutics NV ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Margins
| Current |
|---|
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Agomab Therapeutics NV (Consolidated) | $0 | View detailsOn track to initiate Phase 2b NOV-ERA study with ontunisertib in FSCD and Phase 2 study with AGMB-447 in IPF in the second half of 2026. Cash runway expected to extend into the first half of 2029 following the $208 million gross proceeds raised in the February 2026 IPO. |
Financials converted at 0.8762 from EUR.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.